INO Inovio Pharma Expected net earnings per share growth this year

A prolonged depletion of cash reserves due to a lack of sales triggered a sharp spike in the annual EPS growth rate, where the figure remains around 50.40. Inovio Pharmaceuticals (INO) maintains a diversified drug portfolio that mitigates regulatory risks, while the creation of a DNA medicine base to combat cancer and viruses lays the foundation for future success, as evidenced by the volatile earnings trend on this chart.

INO Inovio Pharma Earnings per share growth in current year (07/04/2022 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Inovio (INO)

- market value and analyst target forecast:

Stock Price Inovio Pharma|INO - Price Target Chart

- market capitalization data:

Market Capitalization Inovio|INO - Enterprise Value

- shareholders' equity book value data:

Net Assets per Share Inovio|INO - Company Book Value|Capitalization to Book Value Ratio inovio.com|INO - Aggregate Company Assets

- debt burden and liquidity indicators:

- earnings and multiples data:

INO - Company Net Income|Forward Earnings Inovio Pharmaceuticals|INO - P/E Multiple|Future Price to Earnings Multiple Inovio Pharmaceuticals|INO - PEG Multiple|EV/EBITDA Multiple Inovio Pharmaceuticals|INO - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Inovio|INO - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months inovio.com|INO - Earnings growth in current year|Earnings growth forecast for next year Inovio Pharmaceuticals

- revenue and sales proceeds data:

INO - Revenue and Sales Volume|Company Future Sales Volume Inovio Pharmaceuticals Inc|INO - P/S Multiple|Market Cap to Future Revenue Ratio Inovio Pharmaceuticals, Inc.|INO - Revenue Growth YoY (Last 12 Months)

Fundamental valuation:INO - Inovio Pharma

The monopoly potential of Inovio Pharmaceuticals (INO) is based on a unique DNA vaccine delivery platform, where future pricing power depends directly on the commercialization of patents. By analyzing the year-over-year growth in earnings per share on GURU.Markets, an investor assesses the net income dynamics per share, which allows for the determination of the business's ability to offset inflationary pressure and confirm the fundamental value of the assets.

Main competitors